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Abstract Nonalcoholic fatty liver disease (NAFLD) is
the most common cause of chronic liver disease in many
developed countries, affecting an estimated 30 % of the
adult population. In this updated clinical review, we sum-
marize the current knowledge regarding the strong asso-
ciation between NAFLD and the risk of coronary heart
disease (CHD) and other functional, structural, and
arrhythmic cardiac complications (e.g., left ventricular
dysfunction, heart valve diseases and atrial fibrillation). We
also briefly discuss the putative biological mechanisms
linking NAFLD with these important extra-hepatic com-
plications. To date, a large body of evidence has suggested
that NAFLD is not simply a marker of CHD and other
functional, structural, and arrhythmic cardiac complica-
tions, but also may play a part in the development and
progression of these cardiac complications. The clinical
implication of these findings is that patients with NAFLD
may benefit from more intensive surveillance and early
treatment interventions aimed at decreasing the risk of
CHD and other cardiac and arrhythmic complications.
Keywords Nonalcoholic fatty liver disease 
Cardiovascular disease  Cardiac disease  Cardiac
arrhythmias  Myocardial dysfunction  Heart valve
diseases
Introduction
Nonalcoholic fatty liver disease (NAFLD)—defined as the
entire histologic spectrum of alcohol-like hepatic condi-
tions observed in nonalcoholic individuals—has become
the most common liver disease worldwide and results in
considerable liver-related mortality and morbidity [1–3].
NAFLD is the third most common indication for liver
transplantation in the USA and is on a trajectory to
become the most common indication within the next
decade [1–3].
Over the past 10 years, it has also become increasingly
clear that NAFLD is a multisystem disease that affects a
variety of extra-hepatic organ systems [4, 5], including the
heart and the vascular system. To date, clear evidence has
indicated that coronary heart disease (CHD) is the primary
cause of morbidity and mortality in patients with NAFLD
[2, 4–7]. As detailed below, convincing evidence also
substantiates the existence of a link between NAFLD and
functional and structural myocardial alterations in both
adults and children with, or without, coexisting features of
the metabolic syndrome (MetS).
This article critically appraises the large body of clinical
data that support a strong association between NAFLD and
the risk of CHD and other cardiac (structural, functional,
and arrhythmic) complications (Fig. 1). We also discuss
the putative biological mechanisms by which NAFLD may
be implicated in the pathophysiology of these cardiac
complications.
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Epidemiological Evidence Linking NAFLD
to Altered Cardiac Structure and Function
Over the past decade, evidence of a significant relationship
between NAFLD and myocardial abnormalities in both
adults and children or adolescents has accumulated. This
relationship appears to be significant even after adjusting
for overweight/obesity, hypertension, and other coexisting
MetS features.
Studies on the Effect of NAFLD on the Left Atrium
and Ventricle
In a study published in 2006, Goland et al. [8] have
reported that adult individuals with NAFLD in the absence
of severe obesity, hypertension, and diabetes have mildly
increased left ventricular (LV) mass and early features of
LV diastolic dysfunction. As detailed in Table 1, after this
pioneering study, several case–control studies have exam-
ined whether NAFLD (as diagnosed either by imaging or
by histology) is associated with cardiac dysfunction and
mildly increased LV mass, independently of coexisting
cardiometabolic risk factors [8–22].
For instance, Kim et al. [14] have found that NAFLD on
ultrasound was associated with LV diastolic dysfunction (as
assessed by tissue Doppler imaging echocardiography) in a
community-based cohort of Korean adults, independently of
established cardiovascular (CVD) risk factors and MetS
features. More recently, VanWagner et al. [16] have exam-
ined 2713 adult participants from the multicenter, commu-
nity-based Coronary Artery Risk Development in Young
Adults (CARDIA) study who underwent concurrent com-
puted tomography quantification of liver fat and compre-
hensive echocardiography with myocardial strain measured
by speckle tracking. Notably, these authors have reported
that patients with NAFLD had lower early diastolic relax-
ation (e0) velocity, higher LVfilling pressure, larger left atrial
(LA) volume, and worse absolute global longitudinal strain
compared with those without NAFLD. After adjustment for
established CVD risk factors, NAFLD remained signifi-
cantly associated with subclinical myocardial remodeling
and dysfunction, thus providing further insight into a
NAFLD/NASH
NAFLD-related cardiac complicaons
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Fig. 1 Spectrum of the most important cardiac complications associated with NAFLD
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possible link between NAFLD and the risk of new-onset
heart failure [16]. In an elegant study involving non-diabetic
adults who underwent magnetic resonance spectroscopy to
quantify myocardial and intra-hepatic triglyceride contents
and magnetic resonance imaging to assess LV function,
visceral adipose tissue, epicardial and pericardial fat, Grane´r
et al. [19] reported that only intra-hepatic triglyceride con-
tent and visceral adipose tissue were associated with sig-
nificant changes in LV structure and function, whereas
myocardial triglyceride content and epicardial and pericar-
dial fat were not associated with LV diastolic dysfunction. A
recent systematic review and meta-analysis of nine cross-
sectional studies have confirmed that NAFLD (diagnosed on
ultrasonography or histology) is associated with subclinical
cardiac abnormalities [23].
Interestingly, as shown in Table 1, a strong association
between NAFLD and LV diastolic dysfunction has also
been documented in patients with type 2 diabetes [11, 12,
17, 20]. For instance, in a recent cross-sectional study
involving 222 consecutive type 2 diabetic patients with no
previous history of CHD, heart failure, moderate-to-severe
heart valve diseases or hepatic disease, who underwent
transthoracic echocardiography (with speckle-tracking
strain analysis), Mantovani et al. [20] have reported that
NAFLD on ultrasound was associated with an approxi-
mately threefold increased risk of mild and/or moderate LV
diastolic dysfunction, even after adjusting for traditional
CVD risk factors, diabetes-related variables, and relevant
echocardiographic parameters. In that study, patients with
NAFLD also had a larger LA volume compared with those
without NAFLD [20]. Similarly, other investigators have
reported a significant association between NAFLD and LA
enlargement or impaired LA deformation, regardless of
pre-existing diabetes [16, 18].
Consistently with this line of evidence, a strong associa-
tion between NAFLD and LV abnormality/dysfunction has
recently been reported in pediatric population. Indeed, as
shown in Table 2, numerous case–control studies have
reported that overweight or obese children with NAFLD
have mildly increased LV mass and early features of LV
dysfunction compared with their counterparts without
NAFLD [24–28]. Notably, these subclinical cardiac abnor-
malities are independent of coexisting cardiometabolic risk
factors.
Some smaller studies that used liver biopsies to diagnose
NAFLD have also shown a significant, graded relationship
between LV abnormality/dysfunction and the severity of
NAFLD histology in both adults and children, suggesting
that hepatic inflammation and fibrosis per se might be a risk
factor in the development and progression of cardiovas-
cular damage [18, 21, 28]. However, future prospective
studies in patients with biopsy-confirmed NAFLD are
needed to improve our understanding of this issue.
Studies on the Effect of NAFLD on the Right Atrium
and Ventricle
Very limited information exists regarding the impact of
NAFLD on right ventricular (RV) function and structure
(Table 1). In a two-dimensional speckle-tracking echocar-
diography study examining the effect of NAFLD on RV
function, Sunbul et al. [22] have reported that patients with
biopsy-proven NAFLD had decreased RV function as
assessed by measurement of global longitudinal strain
compared to age- and sex-matched healthy controls.
Moreover, NAFLD patients with hepatic fibrosis had lower
RV function than those without hepatic fibrosis. Logistic
regression analysis revealed that higher NAS score (using
the NASH Clinical Research Network scoring system)
independently predicted impaired RV function among
these patients [22].
Therefore, according to the evidence from published
studies, it is plausible to assume that NAFLD is strongly
associated with subclinical myocardial remodeling and
dysfunction that may be linked to an increased risk of
developing heart failure over time. Regarding this, some
large population-based studies have recently shown that
mildly elevated serum liver enzymes in the absence of
excessive alcohol consumption (i.e., a proxy of NAFLD)
are long-term, independent predictors of new-onset heart
failure [29–31]. However, additional prospective studies
using more accurate methods for diagnosing NAFLD are
needed to examine the association between NAFLD and
the risk of heart failure.
Tables 1 and 2 summarize the relevant data from the
principal case–control studies that have examined the
effect of NAFLD on cardiac structure and function in both
adults and children.
Epidemiological Evidence Linking NAFLD
to Heart Valve Diseases
As summarized in Table 3, recent studies have suggested
that NAFLD is independently associated with the presence
of cardiac calcification in both the aortic and mitral valves in
both non-diabetic and type 2 diabetic individuals [32–34].
Aortic-valve sclerosis (AVS), defined as focal or diffuse
thickening and calcification of the aortic leaflets without
restriction of leaflet motion, is very common in adults
[65 years of age (occurring in up to 30 % of individuals
over the age of 65) [35]. AVS shares multiple risk factors
with CHD and predicts all-cause and CVD mortality,
independently of traditional cardiovascular risk factors, in
both patients with and without type 2 diabetes [35–37].
Similarly, mitral annulus calcification (MAC) is a common
finding in the elderly (approximately 15 % of adults
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[65 years have MAC on echocardiography) and is also
associated with adverse CVD outcomes [37, 38].
In a large community-based study including 2212 Ger-
man men and women (aged 45–81 years), Markus et al.
[32] have shown, for the first time, that NAFLD diagnosed
on ultrasound was associated with an increased prevalence
of AVS independent of multiple cardiometabolic risk fac-
tors. Bonapace et al. [33] have found that NAFLD and
AVS were strictly interrelated after adjustment for major
confounding factors in a sample of 180 consecutive type 2
diabetic patients. Moreover, Mantovani et al. [34] have
recently conducted a cross-sectional study of 247 consec-
utive type 2 diabetic patients with no previous history of
heart failure, moderate-to-severe heart valve diseases, or
known hepatic diseases. In this study, 26.3 % of patients
had isolated AVS or isolated MAC, and both valves were
affected in 17.4 % of patients. NAFLD was associated with
a 3.5-fold increased rate of AVS, MAC, or both. Adjust-
ments for age, sex, waist circumference, smoking, blood
pressure, hemoglobin A1c, lipids, kidney function param-
eters, medication use, CHD, and echocardiographic
parameters did not appreciably weaken this association.
Notably, when the relationships between NAFLD and AVS
or between NAFLD and MAC were analyzed separately,
NAFLD remained associated with a 2.5-fold to 3-fold
higher rate of either AVS or MAC after adjustment for
potential confounding variables.
Although further studies are needed, these findings
collectively suggest that valvular calcification of the aortic
and mitral valves might represent a further link underpin-
ning the increased risk of CVD events observed among
patients with NAFLD.
Epidemiological Evidence Linking NAFLD
to Cardiac Arrhythmias
NAFLD and Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained
arrhythmia observed in clinical practice, and its prevalence
is expected to substantially increase over the next few
decades because of an aging population and improvements
in cardiovascular treatments [39].
Although the first description of the concurrence of
peripheral artery disease and AF in a patient with type 2
diabetes and fatty liver was reported in the early 1950s
[40], some population-based cohort studies have recently
examined the impact of NAFLD on the risk of incident AF
[41, 42]. The Framingham Heart Study investigators have
shown that impaired liver function, as assessed by eleva-
tion of serum transaminases, was independently associated
with an increased risk of incident AF over 10 years of
follow-up among 3744 white adults who were free of AF at
baseline [41]. Similar findings have been reported in
another population-based study, which involved more than
9000 adults followed up for a mean period of 12 years [42].
Recently, in two subsequent observational studies, Tar-
gher et al. [43] have reported that patients with type 2
diabetes and NAFLD on ultrasound had an increased
prevalence of permanent or persistent AF and were also
more likely to develop incident AF over a 10-year follow-
up period compared with those without NAFLD [44].
Interestingly, the association between NAFLD and the risk
of AF in these two studies remained significant even after
adjustment for multiple AF risk factors [43, 44].
Finally, in a prospective study involving approximately
1000 middle-aged Finnish individuals, who were followed
up for a mean period of 16.3 years, Ka¨ra¨ja¨ma¨ki et al. [45]
have reported that NAFLD on ultrasound was associated
with an approximately twofold increased risk of incident
AF, independently of age, sex, body mass index, waist
circumference, alcohol consumption, smoking, blood
pressure, diabetes status, serum alanine aminotransferase
(ALT) levels, insulin resistance, atrial natriuretic peptide
levels, C-reactive protein levels, and echocardiographic
parameters.
To date, detailed information regarding the underlying
mechanisms of increased AF risk among patients with
NAFLD is lacking. Although impaired atrial conduction
plays a role in the pathophysiology of AF, there is only one
small study to date that has investigated atrial conduction
properties in NAFLD. In this pilot case–control study,
NAFLD patients without clinical diagnosis of hyperten-
sion, diabetes, or cardiac diseases had longer interatrial and
intra-atrial electromechanical delay intervals (by tissue
Doppler echocardiography) and higher P-wave dispersion
(by a standard 12-lead electrocardiogram) compared with
healthy controls [46].
NAFLD and Ventricular Arrhythmias
To date, there is a lack of published data regarding the
association between NAFLD and the risk of ventricular
arrhythmias, which are established risk factors for sudden
cardiac death. Heart rate variability and heart rate-cor-
rected QT (QTc) interval prolongation on standard elec-
trocardiogram have been proposed as useful tools for
identifying patients at risk of sudden cardiac death. For
instance, it is known that QTc interval prolongation is a
powerful risk factor for ventricular arrhythmias, and is also
associated with increased cardiac mortality in both patients
with and without diabetes [47, 48].
In a recent study involving 400 outpatients with type 2
diabetes without a documented history of AF, moderate-to-
severe heart valve diseases, hepatic disease, or excessive
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alcohol consumption [49], the presence and severity of
ultrasonographic NAFLD were found to be associated with
a 2.2-fold increased rate of prolonged QTc interval dura-
tion, independently of age, sex, hypertension, diabetes-re-
lated variables, and other comorbid conditions. Of note, the
exclusion of those with established CHD from the analysis
did not appreciably weaken this association [49].
More recently, Hung et al. [50] have examined whether
the association between NAFLD and QTc interval pro-
longation was also observed in the general population. The
authors found that the severity of NAFLD on ultrasound
was associated with a higher risk of QTc interval prolon-
gation, independently of many cardiometabolic risk fac-
tors. Notably, such association was consistent in all
subgroups of patients examined.
Collectively, although the arrhythmogenic potential of
NAFLD requires further confirmation in future follow-up
studies, we believe that this field of research is promising,
and that the pathophysiological pathways that involve the
contribution of NAFLD to chronic inflammation, hyper-
coagulation, and insulin resistance might provide potential
therapeutic targets for the prevention and treatment of
myocardial remodeling and electrophysiological abnor-
malities of the myocardium in patients with NAFLD [43,
44, 51].
Table 3 summarizes the principal studies that have
examined the association between NAFLD and the risk of
cardiac arrhythmias (mainly atrial fibrillation).
Epidemiological Evidence Linking NAFLD
to Coronary Heart Disease
The negative impact of NAFLD on the risk of CHD/CVD
has generated intense scientific interest over the past dec-
ade [2, 4–7]. This risk deserves particular attention because
it has important clinical implications for screening and
surveillance strategies for the growing number of patients
with NAFLD. In addition, the increased CVD risk in
patients with NAFLD is the aspect of the condition that is
most amenable to medical management that could improve
clinical outcomes of these patients.
Prevalence of Subclinical CHD
Several cross-sectional studies have shown that NAFLD is
associated with an increased coronary artery calcium
(CAC) score, which is a marker of early atherosclerosis and
a powerful predictor of CVD events [7, 52]. NAFLD has
been consistently associated with increasing CAC scores
beyond traditional risk factors in Asians [53–55], African-
Americans [56], and American volunteers [57]. A recent
meta-analysis of 27 cross-sectional studies has reported a
strong association of NAFLD not only with CAC score but
also with other markers of subclinical atherosclerosis, such
as increased carotid intima-media thickness, reduced flow-
mediated vasodilation, and increased arterial stiffness. All
of these associations are independent of traditional car-
diovascular risk factors and MetS features across a wide
range of patient populations [58].
Moreover, some studies have also shown that coronary
flow reserve, an index of coronary microcirculation, is
reduced in patients with NAFLD, independently of multi-
ple potential confounders [59–61].
Prevalence of Clinical CHD
Two Italian studies of type 2 and type 1 diabetic outpatients
[62, 63] as well as a community-based study from Taiwan
[64] have found that NAFLD on ultrasound was associated
with an increased prevalence of clinically manifest CHD,
independently of multiple CVD risk factors. Similarly, the
Framingham Heart Study investigators reported a signifi-
cant association of NAFLD with subclinical CVD out-
comes (CAC and abdominal artery calcium scores),
independent of many metabolic diseases/traits, with a trend
toward association between NAFLD and prevalent clinical
CVD [65]. Conversely, ultrasonography-diagnosed
NAFLD was not found to be associated with prevalent
CHD among diabetic patients in a multiracial Asian hos-
pital clinic population [66].
Many cross-sectional studies have shown that patients
with NAFLD have an increased rate of CHD at coronary
angiography, independently of traditional cardiovascular
risk factors [67–71]. The existence of an independent
association between NAFLD and increased CHD preva-
lence has further been confirmed by a recent meta-analysis
[72]. Moreover, evidence has also supported a strong,
graded relationship between NAFLD and the angiographic
severity of CHD [70, 73–75]. Worryingly, NAFLD has also
been independently associated with the presence of high-
risk coronary atherosclerotic plaques [76–78], impaired
myocardial perfusion, and adverse outcomes following
primary percutaneous coronary interventions [79], which
can be attributed to an increased risk of in-stent restenosis
after bare metal stenting in native coronary arteries [80].
Incidence of Clinical CHD
In this review, we have not discussed the large number of
population-based cohort studies that used elevated serum
liver enzymes to diagnose NAFLD. These studies have
consistently shown a strong association between mildly
elevated serum liver enzyme levels (mainly serum gamma-
glutamyltransferase [GGT]) and the subsequent risk of CVD
events and mortality in both men and women [7, 81–83].
Dig Dis Sci (2016) 61:1246–1267 1255
123
Author's personal copy
In patients with NAFLD diagnosed with imaging tech-
niques (Table 4), several prospective studies have reported
that NAFLD is associated with an increased risk of fatal
and non-fatal CVD events, independently of multiple car-
diometabolic risk factors, both in patients with and without
type 2 diabetes [84–97]. A study addressing CHD as a pre-
specified outcome has also shown that patients with
NAFLD have a higher 10-year risk of CHD as calculated
by the Framingham risk score than the matched control
population, thus proving the clinical utility of the Fram-
ingham risk score in this group of patients [91].
Moreover, the severity of NAFLD (as diagnosed by
imaging) appears to be associated with higher risk of
adverse CVD outcomes. A prospective population-based
Finnish study with a relatively long follow-up period has
reported that severe ultrasonographic NAFLD was inde-
pendently associated with an increased risk of fatal and
non-fatal CVD events [94]. A large retrospective study has
also found that moderate-to-severe NAFLD diagnosed on
computed tomography was associated with an increased
risk of CVD events over a 7-year follow-up period; how-
ever, this association disappeared after adjustment for
coexisting CVD risk factors [95].
Other recent prospective studies examining the associ-
ation between NAFLD and incident CVD events have
provided conflicting results. Data from the Third National
Health and Examination Survey (NHANES-III) database,
whose significance is limited by the inclusion of individ-
uals with mild hepatic steatosis within the control arm,
have shown that NAFLD on ultrasound did not signifi-
cantly predict the risk of all-cause and cause-specific
(CVD, liver, and cancer) mortality in US adults during a
mean follow-up period of 14 years [88, 89]. Interestingly,
the latest analysis of the same NHANES-III cohort found
that patients with NAFLD and advanced hepatic fibrosis (as
estimated by NAFLD fibrosis score and other noninvasive
score systems) as well as those with NAFLD and MetS
were indeed at increased risk of all-cause and CVD mor-
tality [92, 93]. Surprisingly, a recent retrospective cohort
study has reported that NAFLD on ultrasound was signif-
icantly associated with a 5-year lower risk of adverse CVD
outcomes in a cohort of 612 patients with clinical indica-
tions for a coronary angiogram [96]. However, it is plau-
sible to assume that the modality of cardiac interventions
(percutaneous coronary intervention or coronary artery
bypass) and changes in lipid-lowering drugs or other
potentially cardioprotective drugs over the follow-up per-
iod may have markedly modified the clinical outcome of
patients with NAFLD (most of whom had a greater severity
of CHD and a worse cardiovascular risk profile at the
baseline) [98].
In patients with NAFLD diagnosed by histology
(Table 4), a number of retrospective natural history studies
with reasonably long follow-up have clearly shown that all-
cause, CVD-related, and liver-related mortality is higher in
patients with NAFLD than in the matched control popu-
lation [99–106]. These studies have also shown that the
severity of hepatic fibrosis is the main determinant of all-
cause and cause-specific mortality, and that CVD is the
leading cause of mortality among these patients [101–106].
Interestingly, although two of these studies have also
shown that patients with NASH, but not those with simple
steatosis, were at higher risk of all-cause and CVD mor-
tality compared with the reference population [102, 104],
this finding was not confirmed by a recent meta-analysis
that concluded that patients with NAFLD had a higher risk
of major CVD events than the matched control population,
but that the severity of NAFLD histology did not further
increase CVD mortality [81]. However, further prospective
studies in patients with biopsy-confirmed NAFLD are
needed to improve understanding of this issue.
Together, the findings from all of these retrospective and
prospective studies support the assertion that NAFLD,
regardless of the diagnostic technique, is significantly
associated with increased CHD/CVD mortality and mor-
bidity in patients either with or without type 2 diabetes.
Some uncertainty, however, remains as to whether NAFLD
is associated with an increased risk of CVD outcomes
beyond the known risk factors. Additional large-scale
prospective studies of a more extensive panel of known
CVD risk factors are needed to draw firm conclusions
about any independent hepatic contribution to the increased
CVD risk observed among patients with NAFLD.
Table 4 summarizes the principal prospective and ret-
rospective studies that have examined the association
between NAFLD (diagnosed either by imaging or by his-
tology) and the risk of CHD/CVD events and mortality.
Putative Biological Mechanisms Linking NAFLD
with Cardiovascular and Cardiac Complications
The pathophysiological mechanisms linking NAFLD with
vascular, structural, and arrhythmic cardiac complications
are not completely understood. NAFLD is associated with
multiple cardiometabolic risk abnormalities, including
abdominal obesity, ectopic fat accumulation, dysglycemia,
insulin resistance, atherogenic dyslipidemia, hypertension,
and altered hormonal and cytokine profiles, which collec-
tively result in the development of a pro-inflammatory, pro-
atherogenic, and pro-thrombotic milieu [2, 4, 6, 7, 107–
110]. Although further research is needed, recent data also
suggest that specific genetic traits (e.g., patatin-like phos-
pholipase domain-containing protein 3 [PNPLA3] and
transmembrane six superfamily member 2 [TM6SF2] gene
variants) may predispose individuals to hepatic as opposed
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to extra-hepatic complications in NAFLD and that NAFLD
may interact with the MetS in the development of
atherosclerosis in both diabetic and non-diabetic individu-
als [2, 111–114].
A consistent and ever-growing line of research has led to
the idea that the liver, the intestine, and the heart constitute
a closely interconnected network that cooperates in the
regulation of lipid metabolism. The physiological orches-
tration of this network may play a role in maintaining the
health of these three organs through complex and inter-
twined interactions between microRNAs, fatty acids, bile
acids, gut microbiota, and hormones; conversely, the per-
turbation of this collaborative network leads to systemic
chronic inflammation, dyslipidemia, and enhanced oxida-
tive stress [115]. Changes in gut microbiota associated with
a variety of other pathophysiological factors, including
aging, lifestyle habits, medication use, and comorbidities
[115], may also modulate the risk of developing the MetS
[116–119], NAFLD/NASH [120–123], and CHD [124–
127].
The link between intestinal dysbiosis, expanded adipose
tissue, and NAFLD, and the signals passing between these
three organs are schematically shown in Fig. 2. This fig-
ure also illustrates the putative role of the liver in NAFLD,
which can subsequently affect the heart and the vascular
system and thus predispose to CHD and other cardiac
complications.
The putative biological mechanisms linking NAFLD,
expanded/inflamed adipose tissue, and intestinal dysbiosis
with cardiovascular and cardiac complications are com-
plex. Both expanded/inflamed adipose tissue and altered
intestinal microbiota are potentially able to influence the
development of, and progression of NAFLD, via produc-
tion of non-esterified fatty acids, pro-inflammatory
cytokines (e.g., tumor necrosis factor alpha and interleukin-
6), short-chain fatty acids (e.g., butyrate, propionate, and
acetate), incretins (e.g., glucagon-like peptide 1), throm-
bospondin-1, and decreased production of adiponectin
levels. As NAFLD develops and liver fat and inflammation
progress (NASH), a variety of changes occur in liver
structure and function, resulting in the production of
atherogenic lipids and lipoproteins, pro-inflammatory fac-
tors, and vasoactive and thrombogenic molecules. These
NAFLD-induced changes have the potential to adversely
influence the risk of CHD, cardiac, and arrhythmic com-
plications. Hepatic production of lipids, atherogenic
lipoproteins, pro-inflammatory cytokines, and vasoactive
and thrombogenic molecules all may increase risk of CHD
and myocardial infarction. Myocardial steatosis, lipotoxi-
city, enhanced oxidative stress, impaired energy home-
ostasis, and increased epicardial/pericardial fat may exert
local adverse effects that result in functional and structural
derangements of the myocardium. With myocardial
remodeling, there is also an increased risk of heart failure
and cardiac arrhythmias.
By preventing the cell injury due to impaired energetic
metabolism, over-production of reactive oxygen species,
mitochondrial DNA mutations, and deregulated apoptotic
and autophagic pathways, the integrity of mitochondria is
a key requirement for the physiological functions of the
liver, heart, and vessel cells. Several lines of evidence
now support a role for mitochondrial dysfunction as a
pathogenic feature shared by CHD and NAFLD/NASH,
which may both be regarded as maladaptive processes
resulting from a ‘‘subcellular organelle stress’’ [128–134].
Angiotensin II, a mediator of cardiohepatic cell damage
and a potential target of treatment [107], may also be
responsible for mitochondrial dysfunction, which occurs
through a protein kinase C-dependent pathway endothelial
cell NADPH oxidase activation and an increased perox-
ynitrite formation. Mitochondrial dysfunction, resulting
from increased angiotensin II activity, may adversely
affect endothelial singlet oxygen and nitric oxide pro-
duction, which may cause circulatory endothelial dys-
function [135].
Presently, it is unclear whether individual molecular
changes play specific roles in the pathophysiology of
NAFLD-related cardiac abnormalities or whether such
cardiac abnormalities may collectively result from the
entire spectrum of hormonal, metabolic, and cytokine
derangements observed among patients with NAFLD. For
example, hypertension and atherogenic dyslipidemia are
two ideal candidates that may account for the accelerated
atherogenesis observed in NAFLD. Lonardo et al. [136]
have reported that NAFLD may accelerate arterial aging by
approximately 10 years. Among the individual MetS
components, hypertension appears to be the component
least associated with NAFLD [3]; however, a recent meta-
analysis based on paired liver biopsies in NAFLD patients
taken at least 1-year apart has found that hypertension
strongly predicts the development of hepatic fibrosis both
in patients with simple steatosis and in those with NASH at
baseline [137]. As previously noted, although some studies
have suggested that NASH is a stronger risk factor for
CVD than simple steatosis [102, 104], the current evidence
is insufficient to support this conclusion [81, 82]. In con-
trast, the idea that ‘‘the more the (liver) fat the higher the
CVD risk’’ is gaining ever-growing interest owing to the
availability of imaging methods enabling an accurate and
reproducible quantification of the liver fat content [138].
Non-high-density lipoprotein cholesterol (non-HDL) levels
play an important role in the link between NAFLD and
CHD risk. Non-HDL hypercholesterolemia is very com-
mon in NAFLD and tends to be specifically associated with
NASH, suggesting that individuals with this lipid abnor-
mality should undergo liver biopsy for staging of their liver
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disease [3]. Consistently with this link, growing evidence
has suggested that statin treatment, in addition to reducing
CVD events and mortality, might also exert beneficial
effects on either NAFLD histology or some of its hepatic
complications, such as advanced fibrosis, portal hyperten-
sion, and hepatocellular carcinoma [107, 139–143].
Experimental studies have suggested that the lysosomal
cholesterol accumulation may contribute to the progression
toward those states of ‘‘sterile’’ inflammation [144], which
are closely related to CHD and NASH, and may, therefore,
represent potential targets for treatment [145].
Increased epicardial fat accumulation is an emerging
cardiovascular risk factor that is closely associated with
abdominal obesity and advanced hepatic fibrosis [21, 146]
and might be, at least in part, implicated in the develop-
ment of CVD outcomes among patients with NAFLD.
Interestingly, increased epicardial and pericardial fat is
associated with increased rates of AF [147] and CHD [148,
149], owing to their anatomical location very close to the
heart to which they can locally deliver pro-inflammatory
and pro-coagulant factors [150, 151].
How could NAFLD mechanistically predispose indi-
viduals to the development and progression of heart valve
calcification? Dyslipidemia does not seem to play a major
role in the development and progression of AVS, and
treatment with statins has not been shown to be effective in
preventing the progression of AVS [152–155]. In contrast,
abdominal overweight/obesity and hypertension are two
risk factors that are shared by AVS and NAFLD [152, 155–
157]. Moreover, fetuin-A, a liver-secreted protein, inhibits
heart valve calcification [158] and is inversely associated
with hepatic and vascular fibrosis in NAFLD [159], thus
suggesting that the more severe forms of NAFLD might, at
least in part, contribute to the development and progression
of AVS or MAC via decreased fetuin-A levels.
It is well established that LV hypertrophy in hyperten-
sive patients is associated with an increased risk of
supraventricular/atrial and ventricular arrhythmias [160].
NAFLD/NASH 
Lipids and Lipoproteins & Insulin resistance
(e.g. VLDL, HDL-C, small, dense LDL-C, 
non-esterified fatty acids)
CARDIAC STEATOSIS, INCREASED PERICARDIAL FAT
AORTIC-VALVE SCLEROSIS, MITRAL ANNULUS CALCIFICATION
CORONARY HEART DISEASE
EXPANDED AND INFLAMED 
ADIPOSE TISSUE
Structural and electrical remodelling
LEFT VENTRICULAR DYSFUNCTION & HYPERTROPHY
CONGESTIVE HEART FAILURE
CARDIAC ARRHYTHMIAS (ATRIAL FIBRILLATION)
ALTERED GUT 
MICROBIOTA
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Endotoxin/bacteria
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Fig. 2 Putative biological mechanisms linking NAFLD, expanded,
and inflamed adipose tissue and altered gut microbiota with cardio-
vascular and cardiac complications. Fiaf fasting-induced adipose
factor (also referred to as angiopoietin-like protein 4), HDL-C high-
density lipoprotein cholesterol, LDL low-density lipoprotein, PAI-1
plasminogen activator inhibitor-1, TGF transforming growth factor
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Interestingly, LV hypertrophy has been found to be asso-
ciated with NAFLD, independently of hypertension and
other established risk factors, in both type 2 diabetic
patients [12] and non-diabetic adults with NAFLD [13].
Moreover, certain evidence based on surrogate indices of
NAFLD severity has also suggested that advanced NAFLD
is associated with (mild) LV hypertrophy in both adults and
children [27, 161]. The concurrent arrhythmogenic role of
cardiac autonomic dysfunction, a common finding in
NAFLD patients [162, 163], is also potentially treatable by
improving body composition and body fat distribution
[164] and by increasing levels of resistance exercise [165].
In summary, derangements spanning subtle subcellular
changes through systemic hemodynamic, metabolic,
hemostatic, hormonal, and cytokine abnormalities, as well
as deregulation in multiple organ systems, may contribute
to the development and progression of CHD/cardiac dis-
eases in patients with NAFLD. A better understanding of
the multiple pathophysiological and molecular pathways
that link NAFLD to CHD/cardiac diseases might aid in the
discovery of novel therapeutic treatments in the near
future.
Conclusions
In the past decade, compelling evidence has substantiated a
strong link between NAFLD and the risk of CHD and other
cardiac (functional, structural, and arrhythmic) complica-
tions in individuals with or without coexisting MetS fea-
tures. In particular, NAFLD is now increasingly recognized
as a risk factor for CHD, with major vascular events rep-
resenting the primary cause of mortality and morbidity
among patients with NAFLD.
Collectively, these findings suggest that patients with
NAFLD may benefit from more careful surveillance and
early treatment interventions to decrease the risk of vas-
cular and cardiac complications. However, there is still
uncertainty regarding the prognostic role of NAFLD in risk
stratification for CHD. Additional large follow-up studies
are needed to establish whether adding NAFLD to the
currently available risk scoring systems will improve CHD/
CVD risk prediction. Moreover, the key question of whe-
ther the prognostic value of NAFLD in the development
and progression of CHD/cardiac diseases is restricted to
NASH or is also associated with simple steatosis remains
unresolved. Finally, more research is needed to gain
mechanistic insights into the pathophysiology linking
NAFLD with CHD/cardiac diseases and to better elucidate
whether NAFLD associated with specific genetic traits
(e.g., PNPLA3-related NAFLD) carries the same cardio-
vascular risk as NAFLD associated with the MetS [166].
Key Messages
• Strong evidence indicates that NAFLD is associated
with an increased risk of cardiovascular disease, inde-
pendently of multiple cardiometabolic risk factors.
• Convincing evidence substantiates a link between
NAFLD and functional and structural myocardial
abnormalities in both adults and children with, or
without, coexisting features of metabolic syndrome.
• Clinicians who manage patients with NAFLD should
not focus only on liver disease but should also
recognize the increased risk of cardiovascular, cardiac,
and arrhythmic complications and undertake early,
aggressive risk factor modification.
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